

- 2 Takissian J, Bonnin RA, Naas T *et al.* NG-test Carba 5 for rapid detection of carbapenemase-producing *Enterobacteriales* from positive blood cultures. *Antimicrob Agents Chemother* 2019; **63**: e00011-19.
- 3 Glupczynski Y, Evrard S, Ote I *et al.* Evaluation of two new commercial immunochromatographic assays for the rapid detection of OXA-48 and KPC carbapenemases from cultured bacteria. *J Antimicrob Chemother* 2016; **71**: 1217-22.
- 4 Wozniak A, Paillavil B, Legarraga P *et al.* Evaluation of a rapid immunochromatographic test for detection of KPC in clinical isolates of Enterobacteriaceae and *Pseudomonas* species. *Diagn Microbiol Infect Dis* 2019; **95**: 131-3.
- 5 Antonelli A, Giani T, Di Pilato V *et al.* KPC-31 expressed in a ceftazidime/avibactam-resistant *Klebsiella pneumoniae* is associated with relevant detection issues. *J Antimicrob Chemother* 2019; **74**: 2464-6.
- 6 Foschi C, Gaibani P, Lombardo D *et al.* Rectal screening of carbapenemase-producing Enterobacteriaceae: a proposed workflow. *J Glob Antimicrob Resist* 2019; doi:10.1016/j.jgar.2019.10.012.
- 7 Gaibani P, Ambretti S, Campoli C *et al.* Genomic characterization of a *Klebsiella pneumoniae* ST1519 resistant to ceftazidime/avibactam carrying a novel KPC variant (KPC-36). *Int J Antimicrob Agents* 2020; **55**: 105816.
- 8 Gaibani P, Campoli C, Lewis RE *et al.* In vivo evolution of resistant subpopulations of KPC-producing *Klebsiella pneumoniae* during ceftazidime/avibactam treatment. *J Antimicrob Chemother* 2018; **73**: 1525-9.
- 9 Gaibani P, Re MC, Campoli C *et al.* Bloodstream infection caused by KPC-producing *Klebsiella pneumoniae* resistant to ceftazidime/avibactam: epidemiology and genomic characterization. *Clin Microbiol Infect* 2019; doi: 10.1016/j.cmi.2019.11.011.
- 10 Oviaño M, Bou G. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the rapid detection of antimicrobial resistance mechanisms and beyond. *Clin Microbiol Rev* 2018; **32**: e00037-18.

J Antimicrob Chemother 2020; **75**: 2013-2014

doi:10.1093/jac/dkaa171

Advance Access publication 17 May 2020

Favipiravir, an antiviral for COVID-19?

Eric A. Coomes^{1*} and Hourmazd Haghbayan^{2,3}

¹Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; ²Division of Cardiology, London Health Sciences Centre, Western University, London, Ontario, Canada; ³Department of Social and Preventive Medicine, Université Laval, Québec, Québec, Canada

*Corresponding author. E-mail: eric.coomes@mail.utoronto.ca

Sir,

A novel coronavirus, SARS-CoV-2, emerged in December 2019 in Wuhan, China, which is spreading far more rapidly than its

predecessors, having already infected millions of patients worldwide as of 19 April 2020.¹ As the scale of the ongoing COVID-19 outbreak has reached pandemic proportions, intensive worldwide public health efforts are underway to control the outbreak. However, as definitive therapies for established COVID-19 remain to be defined, significant interest exists in repurposing existing antiviral agents for use against COVID-19.

Favipiravir triphosphate is a purine nucleoside analogue, which acts as a competitive inhibitor of RNA-dependent RNA polymerase.² It has activity against influenza A and B, including activity against oseltamivir- and zanamivir-resistant influenza viruses, several agents of viral haemorrhagic fever and SARS-CoV-2 *in vitro*.²⁻⁴ Favipiravir is approved for novel epidemic influenza strains that are unresponsive to standard antiviral therapies in Japan.

Favipiravir was identified to have activity *in vitro* against SARS-CoV-2, albeit requiring a high concentration compared with chloroquine or remdesivir (EC₅₀ = 61.88 µM).³ Despite a similarly elevated EC₅₀ identified for favipiravir and Ebola virus, it was identified in previous animal models to be highly effective as post-exposure prophylaxis for mice exposed to Ebola virus challenges, with rapid virological response preventing mortality.^{5,6} Based on the dosing strategies and pharmacokinetic data from human influenza trials, an intensified dosing strategy of 6000 mg loading on day 1 followed by maintenance therapy of 1200 mg orally twice daily for 10 days was employed in a single-arm clinical trial for Ebola virus disease in Guinea.⁷

In a retrospective analysis of 124 patients with Ebola virus disease in Sierra Leone, those treated with favipiravir had a significantly higher survival rate compared with patients receiving supportive management (56.4% versus 35.3%; *P* = 0.027).⁸ Patients received favipiravir 800 mg orally twice daily on day 1 and 600 mg orally twice daily on days 3-11. Viral loads were quantified for 35 patients twice during their hospitalization and were significantly reduced amongst patients receiving favipiravir.

Favipiravir has also been used as pharmacological post-exposure prophylaxis for Ebola virus disease.⁹ In a case series of four healthcare workers with higher risk Ebola virus exposures, including two hollow-bore needlestick injuries, none of the patients who received 10 days of high-dose favipiravir developed Ebola virus disease.

Early clinical experience with favipiravir for COVID-19 is promising. An open-label non-randomized trial of 80 patients with COVID-19 in China identified a significant reduction in the time to SARS-CoV-2 viral clearance in patients treated with favipiravir compared with historical controls treated with lopinavir/ritonavir.¹⁰ Patients with mild or moderate COVID-19 were enrolled within 7 days from disease onset; those ≥ 75 years old, with severe or critical disease, chronic liver disease or end-stage renal disease were excluded. Patients in the intervention arm received favipiravir 1600 mg orally twice daily on day 1 followed by 600 mg orally twice daily on days 2-14. Both arms were co-treated with inhaled IFN-α1b 60 µg twice daily and therapy was continued until viral clearance, up to a maximum of 14 days. Thirty-five patients were assigned to favipiravir and 45 patients to lopinavir/ritonavir, with a median age of 47 years (IQR = 35.8-61); 13.7% were ≥ 65 years

old. There was a significant reduction in the median time to viral clearance with favipiravir (4 days; IQR = 2.5–9) compared with lopinavir/ritonavir (11 days; IQR = 8–13; $P < 0.001$). Further, by day 14, 91.4% of patients in the favipiravir arm had radiographic improvement versus 62.2% in the lopinavir/ritonavir arm. There was a significantly lower rate of adverse events in patients receiving favipiravir (11.4% versus 55.6%; $P < 0.01$).

Given the demonstrated *in vitro* activity of favipiravir against SARS-CoV-2 and signals of benefit in early clinical experience for COVID-19, further studies are urgently needed. The results of several ongoing randomized controlled trials to assess the efficacy of favipiravir for COVID-19 will further elucidate the role of favipiravir in the management of the ongoing coronavirus pandemic.

Funding

No funding was obtained specifically for this article.

Transparency declarations

E.A.C. is a co-investigator on applications to conduct a clinical trial of favipiravir for COVID-19. H.H.: none to declare.

References

- 1 Wang C, Horby PW, Hayden FG *et al*. A novel coronavirus outbreak of global health concern. *Lancet* 2020; **395**: 470–3.
- 2 Furuta Y, Gowen BB, Takahashi K *et al*. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. *Antiviral Res* 2013; **100**: 446–54.
- 3 Wang M, Cao R, Zhang L *et al*. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*. *Cell Res* 2020; **30**: 269–71.
- 4 Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. *Pharmacol Ther* 2020; **209**: 107512.
- 5 Oestereich L, Ludtke A, Wurr S *et al*. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. *Antiviral Res* 2014; **105**: 17–21.
- 6 Smither SJ, Eastaugh LS, Steward JA *et al*. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. *Antiviral Res* 2014; **104**: 153–5.
- 7 Sissoko D, Laouenan C, Folkesson E *et al*. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. *PLoS Med* 2016; **13**: e1001967.
- 8 Bai CQ, Mu JS, Kargbo D *et al*. Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)—Sierra Leone, 2014. *Clin Infect Dis* 2016; **63**: 1288–94.
- 9 Jacobs M, Aarons E, Bhagani S *et al*. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. *Lancet Infect Dis* 2015; **15**: 1300–4.
- 10 Cai Q, Yang M, Liu D *et al*. Experimental treatment with favipiravir for COVID-19: an open-label control study. *Engineering* 2020; doi:10.1016/j.eng.2020.03.007.

J Antimicrob Chemother 2020; **75**: 2014–2015

doi:10.1093/jac/dkaa193

Advance Access publication 17 May 2020

COVID-19 infection also occurs in patients taking hydroxychloroquine

M. Lahouati^{1,2}, E. Mériglier¹, L. Martin³, S. Bouchet⁴, A. Desclaux³ and F. Bonnet^{1,5*}

¹CHU de Bordeaux, Hôpital Saint-André, Service de Médecine Interne et Maladies Infectieuses, F-33000 Bordeaux, France;

²CHU de Bordeaux, Hôpital Saint-André, Service de Pharmacie Clinique, F-33000 Bordeaux, France; ³CHU de Bordeaux, Hôpital Pellegrin, Service de Maladies Infectieuses et Tropicales, F-33000 Bordeaux, France; ⁴CHU de Bordeaux, Hôpital Pellegrin, Service de Pharmacologie, F-33000 Bordeaux, France; ⁵Université de Bordeaux, Bordeaux Population Health, INSERM U1219, F-33000 Bordeaux, France

*Corresponding author. E-mail: fabrice.bonnet@chu-bordeaux.fr

Sir,

Hydroxychloroquine is a synthetic antimalarial drug that has also been used for its immunomodulatory activity in lupus erythematosus, rheumatoid arthritis and other inflammatory diseases for years.

Two *in vitro* studies in China have demonstrated the inhibitory activity of hydroxychloroquine against SARS-CoV-2^{1,2} with a greater potency compared with chloroquine, in addition to its immunomodulatory activity.

Clinical data from case series and non-randomized controlled studies suggest hydroxychloroquine may have a positive impact on the outcome of COVID-19 infection and hydroxychloroquine has been largely introduced as a standard of care in many guidelines without formal proof of efficacy. Many ongoing trials are evaluating its efficacy versus standard of care and antivirals. It has also been suggested that hydroxychloroquine could prevent COVID-19 infection and other trials are evaluating hydroxychloroquine alone or in combination in a prevention strategy.³

Here we report on two severe cases of COVID-19 in patients already using hydroxychloroquine for a long time to treat inflammatory disease.

Observation 1

A 64-year-old woman was admitted to hospital for fever. She had a long-term history of treatment by hydroxychloroquine 400 mg once daily for mixed connectivitis. She had been experiencing major headaches, myalgias, fever and nausea for 10 days. Family members had been previously